WHO’s Access to Medicines and Health Product Division (WHO/MHP) confirms that, as of 01 January 2020, all activities and functions within the scope of WHO’s Department of Essential Medicines and Health Products (WHO/EMP) regarding International Nonproprietary Names (INN) are now carried out by WHO’s Access to Medicines and Health Products Division (MHP), namely through the Health Product Policy and Standards Department. WHO’s MHP division is not a new entity or separate organization, but a restructured office that remains part of WHO. WHO/MHP confirms that WHO/MHP is bound by the commitments made by WHO/EMP to protect FDA-provided non-public information in accordance with the mutual confidentiality arrangement entered into between WHO/EMP and FDA, effective 31 August 2017 (the “2017 Arrangement”), and that WHO/MHP will continue to protect any non-public information previously shared by FDA with WHO/EMP in accordance with the provisions of the 2017 Arrangement.  For the avoidance of doubt, FDA shall also continue to treat and protect—in accordance with the provisions of the 2017 Arrangement—any non-public or confidential information that has been or will be provided by WHO/MHP thereunder.